Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

ChitogenX Inc. (CHNXF)

Compare
0.0050
0.0000
(0.00%)
At close: April 18 at 4:00:00 PM EDT
Loading Chart for CHNXF
  • Previous Close 0.0000
  • Open 0.0071
  • Bid 0.0063 x --
  • Ask 0.0130 x --
  • Day's Range 0.0071 - 0.0071
  • 52 Week Range 0.0050 - 0.0500
  • Volume 4,000
  • Avg. Volume 221
  • Market Cap (intraday) 599,710
  • Beta (5Y Monthly) -1.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date May 26, 2025 - May 30, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.

www.chitogenx.com

--

Full Time Employees

January 31

Fiscal Year Ends

Recent News: CHNXF

View More

Performance Overview: CHNXF

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

CHNXF
66.67%
S&P/TSX Composite index (^GSPTSE)
1.74%

1-Year Return

CHNXF
87.29%
S&P/TSX Composite index (^GSPTSE)
11.44%

3-Year Return

CHNXF
97.52%
S&P/TSX Composite index (^GSPTSE)
10.58%

5-Year Return

CHNXF
98.90%
S&P/TSX Composite index (^GSPTSE)
68.47%

Compare To: CHNXF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CHNXF

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    595.46k

  • Enterprise Value

    3.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -152.34%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -1.55M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    48k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -41k

Research Analysis: CHNXF

View More

Company Insights: CHNXF

Research Reports: CHNXF

View More

People Also Watch